{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:01:11Z","timestamp":1783468871898,"version":"3.55.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.ahj.2020.05.002","type":"journal-article","created":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T08:50:31Z","timestamp":1589359831000},"page":"49-59","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":117,"special_numbering":"C","title":["Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial"],"prefix":"10.1016","volume":"226","author":[{"given":"Renato D.","family":"Lopes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane Vieira Scarlatelli","family":"Macedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Gabriel Melo","family":"de Barros e Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata Junqueira","family":"Moll-Bernardes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme","family":"D'Andr\u00e9a Saba Arruda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Silvestre","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denilson Campos","family":"de Albuquerque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian","family":"Mazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayara Fraga","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia Zerbinatti","family":"Salvador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Michael","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Granger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga Ferreira","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2020.05.002_bb0005","unstructured":"World Health Organization. Coronavirus disease 2019 (COVID-19): situation report, 51. Available at: https:\/\/www.who.int\/docs\/default-source\/coronaviruse\/situation-reports\/20200311-sitrep-51-covid-19.pdf?sfvrsn=1ba62e57_10. Published: March 11, 2020. Accessed April 24, 2020."},{"key":"10.1016\/j.ahj.2020.05.002_bb0010","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1056\/NEJMsb1905390","article-title":"Creating a framework for conducting randomized clinical trials during disease outbreaks","volume":"382","author":"Dean","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2020.05.002_bb0015","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMp1604635","article-title":"The emergence of the randomized, controlled trial","volume":"375","author":"Bothwell","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2020.05.002_bb0020","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/cid\/cix1032","article-title":"Rigorous clinical trial design in public health emergencies is essential","volume":"66","author":"Ellenberg","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ahj.2020.05.002_bb0025","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jacc.2019.11.043","article-title":"New approaches to conducting randomized controlled trials","volume":"75","author":"Fanaroff","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2020.05.002_bb0030","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1056\/NEJMp1310102","article-title":"The randomized registry trial\u2014the next disruptive technology in clinical research?","volume":"369","author":"Lauer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2020.05.002_bb0035","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nrcardio.2015.33","article-title":"Registry-based randomized clinical trials\u2014a new clinical trial paradigm","volume":"12","author":"James","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.ahj.2020.05.002_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.pcad.2020.03.001","article-title":"Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): evidence from a meta-analysis","author":"Lippi","year":"2020","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.ahj.2020.05.002_bb0045","article-title":"Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China","author":"Ruan","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ahj.2020.05.002_bb0050","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.tips.2004.04.001","article-title":"ACE2: from vasopeptidase to SARS virus receptor","volume":"25","author":"Turner","year":"2004","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.ahj.2020.05.002_bb0055","doi-asserted-by":"crossref","unstructured":"Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol 2020;94:e00127\u201320.","DOI":"10.1128\/JVI.00127-20"},{"key":"10.1016\/j.ahj.2020.05.002_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.mayocp.2020.03.026","article-title":"Angiotensin-converting enzyme 2 and antihypertensives (angiotensin receptor blockers and angiotensin-converting enzyme inhibitors) in coronavirus disease 2019","author":"Sanchis-Gomar","year":"2020","journal-title":"Mayo Clinic Proc"},{"key":"10.1016\/j.ahj.2020.05.002_bb0065","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.4812","article-title":"COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence?","author":"Patel","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2020.05.002_bb0070","doi-asserted-by":"crossref","DOI":"10.1038\/s41581-020-0279-4","article-title":"Controversies of renin\u2013angiotensin system inhibition during the COVID-19 pandemic","author":"South","year":"2020","journal-title":"Nature Reviews Nephrology"},{"key":"10.1016\/j.ahj.2020.05.002_bb0075","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s13054-017-1823-x","article-title":"A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome","volume":"21","author":"Khan","year":"2017","journal-title":"Crit Care"},{"key":"10.1016\/j.ahj.2020.05.002_bb0080","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1161\/01.HYP.0000040264.15961.48","article-title":"ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time","volume":"40","author":"Brown","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.ahj.2020.05.002_bb0085","unstructured":"Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA Epub ahead of print; doi:https:\/\/doi.org\/10.1001\/jama.2020.677."},{"key":"10.1016\/j.ahj.2020.05.002_bb0090","article-title":"Treatment with ACE-inhibitors is associated with less severe disease with SARS-Covid-19 infection in a multi-site UK acute hospital trust","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.ahj.2020.05.002_bb0095","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"Whelton","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2020.05.002_bb0100","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2020.05.002_bb0105","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2020.05.002_bb0110","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1259\/0007-1285-44-526-793","article-title":"Repeated assessment of results in clinical trials of cancer treatment","volume":"44","author":"Haybittle","year":"1971","journal-title":"Brit J Radiol"},{"key":"10.1016\/j.ahj.2020.05.002_bb0115","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1177\/1740774518823551","article-title":"Assessing the impact of efficacy stopping rules on the error rates under the multi-arm multi-stage framework","volume":"16","author":"Blenkinsop","year":"2019","journal-title":"Clin Trials"},{"key":"10.1016\/j.ahj.2020.05.002_bb0120","doi-asserted-by":"crossref","unstructured":"Vincent JL, Taccone FS. Understanding pathways to death in patients with COVID-19. Lancet Respir Med. 2020;Epub ahead of print. doi: https:\/\/doi.org\/10.1016\/S2213-2600(20)30165-X.","DOI":"10.1016\/S2213-2600(20)30165-X"},{"key":"10.1016\/j.ahj.2020.05.002_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(20)30079-5","article-title":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study","author":"Yang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ahj.2020.05.002_bb0130","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2020.05.002_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(20)30116-8","article-title":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?","volume":"8","author":"Fang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ahj.2020.05.002_bb0140","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/s41371-018-0138-y","article-title":"A systematic review and network meta-analysis of the comparative efficacy of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertension","volume":"33","author":"Dimou","year":"2019","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.ahj.2020.05.002_bb0145","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/jamainternmed.2014.348","article-title":"Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis","volume":"174","author":"Cheng","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ahj.2020.05.002_bb0150","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2174\/1573403X09666131117174414","article-title":"Acute decompensated heart failure update","volume":"11","author":"Teerlink","year":"2015","journal-title":"Curr Cardiol Rev"},{"key":"10.1016\/j.ahj.2020.05.002_bb0155","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","article-title":"Renin-angiotensin-aldosterone system inhibitors in patients with COVID-19","volume":"382","author":"Vaduganathan","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2020.05.002_bb0160","doi-asserted-by":"crossref","DOI":"10.1161\/HYPERTENSIONAHA.120.15082","article-title":"Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers","author":"Danser","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.ahj.2020.05.002_bb0165","article-title":"Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19","author":"Zhang","year":"2020","journal-title":"Circ Res"},{"key":"10.1016\/j.ahj.2020.05.002_bb0170","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2020.1624","article-title":"Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China","author":"Li","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2020.05.002_bb0175","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1056\/NEJMoa1308789","article-title":"Thrombus aspiration during ST-segment elevation myocardial infarction","volume":"369","author":"Fr\u00f6bert","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2020.05.002_bb0180","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12890-019-0809-7","article-title":"REgistry-based randomized controlled trial of treatment and Duration and mortality in long-term OXygen therapy (REDOX) study protocol","volume":"19","author":"Sundh","year":"2019","journal-title":"BMC Pulm Med"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870320301381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870320301381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:57:53Z","timestamp":1762077473000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870320301381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":36,"alternative-id":["S0002870320301381"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2020.05.002","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2020.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}